Pharma rivals are fighting Covid together. Why stop there?
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
The Business Standard

Saturday
February 04, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
SATURDAY, FEBRUARY 04, 2023
Pharma rivals are fighting Covid together. Why stop there?

Panorama

Max Nisen, Bloomberg
26 August, 2020, 01:30 pm
Last modified: 26 August, 2020, 03:24 pm

Related News

  • Hong Kong says 'hello' to woo back visitors after Covid
  • How pharmas performed against high headwinds
  • US to end Covid-19 emergency declarations on 11 May
  • Covid remains a public health emergency, says WHO
  • Holiday trips within China surge after lifting of Covid curbs

Pharma rivals are fighting Covid together. Why stop there?

Some of the world’s biggest drugmakers are making unusual deals to get more medicine to more people at a lower cost. Not a bad idea

Max Nisen, Bloomberg
26 August, 2020, 01:30 pm
Last modified: 26 August, 2020, 03:24 pm
The urgent need for effective Covid-19 treatments and vaccines is causing a shift in drugmakers’ priorities. Photographer:  Andrey Rudakov/Bloomberg
The urgent need for effective Covid-19 treatments and vaccines is causing a shift in drugmakers’ priorities. Photographer: Andrey Rudakov/Bloomberg

Pandemics make for strange bedfellows and behavior in the pharmaceutical industry.

The world is relying on drugmakers' expertise to get us out of the Covid-19 crisis — initially with treatments to help lessen the risks from contracting the virus, and then ultimately with a vaccine. The high pressure, enormous need, and global attention are leading companies to try new things on the fly. Just last week, Regeneron Pharmaceuticals Inc. signed a pact with its erstwhile rival Roche Holding AG aimed at substantially boosting supplies of a potential treatment for Covid-19; it even made some monetary sacrifices to do so. And that's only the latest example. 

Much of what's happening represents a war-time type response to a unique situation, and it may not be repeated. These are for-profit companies, after all, and they will act accordingly. But from an unprecedented vaccine hunt to international manufacturing deals, the drug industry's response shows the possibilities of what a more collaborative medicine market could bring.  

Take the Regeneron-Roche deal, under which Regeneron will sell its promising antibody therapy in the US, and Roche will handle the rest of the world. The companies will carry their own manufacturing and distribution costs and divide development expenses and profit. Roche's muscle could more than triple capacity, according to Regeneron. 

Typically, Roche would pay a hefty price for a cut of a promising drug's potential sales. In this case, Regeneron is forgoing that customary upfront payment and surety in favor of maximizing supply during the pandemic. Regeneron won't be able to satisfy global demand on its own, and Roche is a giant in the field of antibody drugs. The bigger company has a lot of incentive to scale up manufacturing; it will receive between 40% and 50% of gross profit.

Regeneron will get nothing but some of its costs covered if it doesn't pan out. However, the company can't sell medicine that it can't make. Picking volume and patient access over a higher profit margin — a tactic drugmakers too rarely embrace — makes sense from a humanitarian and business perspective.

While the Regeneron-Roche deal focuses on antibody manufacturing, uncommon partnerships and arrangements are forming in other areas as well to meet various pressing needs. Here are just a few:

  • Ensuring worldwide supply: Gilead Sciences Inc., the company behind remdesivir —  one of the few Covid treatments available — freely gave away a license so that several generic drugmakers can make a low-cost version for developing countries, something that generally doesn't happen for a brand-new medicine and will dramatically boost the drug's availability.
  • Collaborating on a vaccine: Fierce competitors Sanofi and GlaxoSmithKline PLC formed a historic partnership under which one will provide the core of a vaccine, and the second a type of booster called an adjuvant. 
  • Pricing for access: Instead of leaving prices to the free market as it often does, the US is behaving like other countries that manage to keep drug costs at a reasonable level by negotiating the price of hundreds of millions of doses of vaccine before they reach the market. It's been helped by non-profit pledges from AstraZeneca PLC and Johnson & Johnson, who are developing two leading candidates.  However, the prices negotiated with companies that aim to make a  profit are lower than the private-market norm for new shots. Uncle Sam is buying the doses and the first wave of vaccines will be free for Americans. It's a sharp contrast to ordinary times, where the world's highest drug prices lead to financial hardship and skipped treatments. 
  • Risk-sharing:  At least one of the US government's Operation Warp Speed vaccine deals includes risk-sharing structures I've never seen in a government contract. The US will pay less for Moderna Therapeutic Inc's vaccine if the company is slow to deliver it. The company also has an opportunity to get a $600 million chunk of money early if it can meet ambitious manufacturing timelines.
  • Fixing a broken market: Infectious disease research, the neglected and unprofitable stepchild of drug development, is being lavished with money and attention. The US alone has committed or promised over $10 billion to six companies and many more are working on novel vaccines. Hopefully, the large sums will convince companies to continue to invest.  

It's great that companies and the government are stepping up. But the moment will be wasted if everything snaps back post-pandemic. Better pricing, more focus on patients and public health, and less duplication of effort are all possible and should be the expectation even when there isn't a crisis. 


Disclaimer: This article first appeared on Bloomberg, and is published by special syndication arrangement

Analysis / Top News

pharmaceutical companies / fighting coronavirus / COVID-19 / Pharmaceutical Industry / Drug makers / Coronavirus / covid-19 vaccine / Covid-19 vaccines / Covid-19 treatment / Coronavirus treatment

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Is the IMF to blame for growing pressure on your wallet?
    Is the IMF to blame for growing pressure on your wallet?
  • Dr Salehuddin Ahmed. Illustration: TBS
    Reforms in banking must to sustain financial sector
  • Why 2012 reforms were not done is a million-dollar question
    Why 2012 reforms were not done is a million-dollar question

MOST VIEWED

  • The trio spearheading the revival of book cover designs
    The trio spearheading the revival of book cover designs
  • Andy Mukherjee. Sketch: TBS
    What makes India's billionaires' support special for Adani
  • While the Padma bridge in operation is changing the lives of millions in the south for the better, passenger rush to Shimulia ghat died down. Photo: Masum Billah
    How are the Shimulia ghat businesses faring after Padma bridge?
  • After so many investments going embarrassingly wrong, as was the case with Sam Bankman-Fried, perhaps tech investors’ preference for less experience will wane. Photo: Bloomberg
    Are you the next Steve Jobs? Good luck raising money in 2023
  • Infographic: TBS
    How to redirect inward remittances to formal channels
  • An elderly couple's lonely battle to save Dhaka's trees
    An elderly couple's lonely battle to save Dhaka's trees

Related News

  • Hong Kong says 'hello' to woo back visitors after Covid
  • How pharmas performed against high headwinds
  • US to end Covid-19 emergency declarations on 11 May
  • Covid remains a public health emergency, says WHO
  • Holiday trips within China surge after lifting of Covid curbs

Features

Andy Mukherjee. Sketch: TBS

What makes India's billionaires' support special for Adani

20h | Panorama
Photo: Rejaul Hafiz Rahi

A jackal farewell

21h | Earth
The trio spearheading the revival of book cover designs

The trio spearheading the revival of book cover designs

22h | Panorama
Six Jeep Wranglers and a special XJ Jeep Cherokee set out into the depths of Lalakhal, Sylhet for an experience of a lifetime. Photo: Ahbaar Mohammad

Jeep Life Bangladesh: A club for Jeep owners to harness the power of their vehicles

1d | Wheels

More Videos from TBS

A proper price formula can help investors to plan big

A proper price formula can help investors to plan big

1d | TBS Round Table
Rumors about Sarika that everyone thinks are true

Rumors about Sarika that everyone thinks are true

1d | TBS Entertainment
Mugging rife in Tejgaon, murder in Wari

Mugging rife in Tejgaon, murder in Wari

1d | TBS Current Affairs
What secrets are hidden behind Adani's wealth?

What secrets are hidden behind Adani's wealth?

1d | TBS Stories

Most Read

1
Bapex calls candidates for job test 9 years after advert!
Bangladesh

Bapex calls candidates for job test 9 years after advert!

2
Leepu realised his love for cars from a young age and for the last 40 years, he has transformed, designed and customised hundreds of cars. Photo: Collected
Panorama

'I am not crazy about cars anymore': Nizamuddin Awlia Leepu

3
Photo: Collected
Energy

8 Ctg power plants out of production

4
The International Monetary Fund (IMF) logo is seen outside the headquarters building in Washington, U.S., September 4, 2018. REUTERS/Yuri Gripas/File Photo
Economy

IMF approves $4.7 billion loan for Bangladesh, calls for ambitious reforms

5
Photo: Collected
Court

Japanese mother gets guardianship of daughters, free to leave country

6
Fund cut as Dhaka's fast-track transit projects on slow spending lane
Infrastructure

Fund cut as Dhaka's fast-track transit projects on slow spending lane

EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net